Trade Setup Buy Target $2.26 Sell Target $2.97 Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated […]
Read MoreTrade Setup Buy Target $3.91 Sell Target $5.11 ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer.
Read MoreTrade Setup Buy Target $7.55 Sell Target $10.14 Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the […]
Read MoreWith the entire world’s focus – financial market or otherwise – turned almost exclusively to coronavirus, social distancing, and how long it is going to take for the world to return to any kind of normalcy in the foreseeable future, it isn’t all that surprising to see market commentary emphasizing health care. I’ve spent enough […]
Read MoreAs an investor that prefers to focus on value, my preference is to emphasize stocks that are currently trading at significant discounts to their basic valuation metrics. That usually means that most of my attention is directed on stocks that are also trading at or near to yearly or historical lows. That also means that […]
Read MoreFor the last few weeks, I believe that one of the biggest reasons investors, and the public at large have been so uncertain is simply because the scope of the spread of COVID-19 infection really is. Shelter-in-place orders in some cities and states followed stay-at-home and self-isolating policies that have taken place pretty much everywhere […]
Read MoreOver the weekend, the focus in news media seems to have shifted a bit. It isn’t that discussion and commentary has materially changed – COVID-19, and its accelerating rate of infection in the U.S. is still front and center – but as it relates to the market and the economy, much of the conversation is […]
Read MoreIf you’re like me, you can really only take so much of the daily commentary on any news media outlet that is entirely and completely fixed on COVID-19. That isn’t to minimize the importance of the crisis-level measures that, I think are appropriately being taken on a national scale to try to slow the spread […]
Read MoreTrade Setup Buy Target $60.15 Sell Target $70.57 Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor […]
Read MoreAt the beginning of my career in the financial industry, I was a licensed rep for one of the largest mutual fund and discount brokerage companies in North America. Looking over the mutual funds that we offered, and digging into their respective investment philosophies was something I found to be really fascinating. It wasn’t just […]
Read MoreTrade Setup Buy Target $4.59 Sell Target $5.88 Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic […]
Read MoreTrade Setup Buy Target $19.59 Sell Target $23.41 Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit […]
Read MoreTrade Setup Buy Target $2.22 Sell Target $2.92 Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company’s lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis.
Read MoreTrade Setup Buy Target $7.25 Sell Target $7.85 Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with […]
Read MoreTrade Setup Buy Target $24.74 Sell Target $26.31 XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, […]
Read More